From: Common genetic variants do not predict recurrent events in coronary heart disease patients
Pravastatin | Placebo | Total | |
---|---|---|---|
Randomised | 4512 | 4502 | 9014 |
Survived to end of RCT (mean 6.1 years) | 4014 | 3868 | 7882 |
Consented to blood sample, high quality DNA extracted | 2524 | 2408 | 4932 (LIPID Genetic cohort) |
LIPID Genetic Cohort (n = 4932) followed for 10 years from end of RCT | |||
All-cause deaths | 792 (31.4%) | 766 (31.8%) | 1558 (31.6%) |
Cardiovascular deaths | 455 (18.0%) | 443 (18.4%) | 898 (18.2%) |
Coronary heart disease deaths | 368 (14.6%) | 359 (14.9%) | 727 (14.7%) |
Cancer deaths | 192 (7.6%) | 183 (7.6%) | 375 (7.6%) |